# TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

> **NCT05980598** · PHASE2 · TERMINATED · sponsor: **Ascendis Pharma A/S** · enrollment: 27 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** TransCon TLR7/8 Agonist
- **DRUG:** Pembrolizumab
- **DRUG:** TransCon IL-2 β/γ

## Key facts

- **NCT ID:** NCT05980598
- **Lead sponsor:** Ascendis Pharma A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-29
- **Primary completion:** 2025-03-28
- **Final completion:** 2025-03-28
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** The Sponsor made the decision to close enrollment as part of a strategic portfolio review.
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05980598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05980598, "TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05980598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*